SPX3,647.29-7.75 -0.21%
DIA291.30-1.42 -0.49%
IXIC10,829.50+26.58 0.25%

BRIEF-Vaxxinity Doses First Subjects In Phase 1 Clinical Trial Of UB-313

BRIEF-Vaxxinity Doses First Subjects In Phase 1 Clinical Trial Of UB-313

Reuters · 09/13/2022 10:08
BRIEF-Vaxxinity Doses First Subjects In Phase 1 Clinical Trial Of UB-313

- Vaxxinity Inc VAXX.O:

  • VAXXINITY ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF UB-313 FOR PREVENTIVE TREATMENT OF MIGRAINE

Source text for Eikon: ID:

Further company coverage: VAXX.O


((Reuters.Briefs@thomsonreuters.com;))